Evidence map›Paper›PMID 42527634›Full record

ArticleNeurosurgical review2026

Stereotactic radiosurgery for spinal cholangiocarcinoma metastases: Clinical outcomes and the role of biologically effective dose thresholds.

Juan J Cardona, Fred C Lam, Mohamed F Al Gharyani, Yusuke S Hori, Deya Abu-Reesh, Louisa Ustrzynski, Sara C Emrich, Armine Tayag, Xuejun Gu, Erqi L Pollom and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Juan J CardonaDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Fred C LamDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Mohamed F Al GharyaniDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Yusuke S HoriDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Deya Abu-ReeshDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Louisa UstrzynskiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Sara C EmrichDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Armine TayagDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Xuejun GuDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Erqi L PollomDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Scott G SoltysDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Gordon LiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Atman DesaiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Melanie Hayden GephartDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
David J ParkDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. djpark@stanford.edu.
Steven D ChangDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.

Funding

TOOLKIT CoreU54CA261717 · NCI · STANFORD UNIVERSITY · PI Melanie Hayden Gephart · 2021 to 2026
$8.9M
NCI NIH HHS U54 CA261717
6 · The paper itself

Abstract

Stereotactic radiosurgery (SRS) has emerged as a promising modality for improving local tumor control (LTC); however, data on its use for spinal metastases (SM) specifically from cholangiocarcinoma remain limited. In this single-institution retrospective analysis, we aimed to evaluate the safety and efficacy of SRS for SM from cholangiocarcinoma, exploring the role of biologically effective dose (BED) thresholds. Demographic, clinical, radiographic, and dosimetric variables, including Bilsky grade, Karnofsky Performance Status (KPS), and BED, were collected. The treatment response was assessed using a combination of radiologic, metabolic, and clinical criteria. Survival outcomes were calculated using Kaplan-Meier methods, and statistical analyses accounted for lesion clustering within patients. Seventeen SM identified in eight patients (mean age 68 years; SD± 8.2 years) were analyzed. The mean lesion volume at the time of treatment was 37.4 cm

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaRadiosurgerySpinal NeoplasmsAgedFemaleHumansMaleMiddle AgedRadiotherapy DosageRetrospective StudiesTreatment OutcomeBiologically effective doseCholangiocarcinomaOverall survivalProgression-free survivalSpinal metastasesStereotactic radiosurgery

Identifiers

PMID42527634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.